Premium
Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab
Author(s) -
Nakano Kenji,
Seto Akira,
Sasaki Toru,
Shimbashi Wataru,
Fukushima Hirofumi,
Yonekawa Hiroyuki,
Mitani Hiroki,
Takahashi Shunji
Publication year - 2019
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25727
Subject(s) - cetuximab , medicine , interstitial lung disease , oncology , incidence (geometry) , epidermal growth factor receptor , lung cancer , head and neck cancer , head and neck squamous cell carcinoma , adverse effect , egfr inhibitors , cancer , lung , colorectal cancer , physics , optics
Background Interstitial lung disease (ILD) is known as a potentially severe adverse event associated with epidermal growth factor receptor (EGFR)‐targeted therapy. The incidence and risk factors of ILD in patients with head and neck squamous cancer (HNSCC) treated with cetuximab, an anti‐EGFR monoclonal antibody, have not been established. Methods We retrospectively reviewed patients with HNSCC who received cetuximab from December 2012 to December 2016 at our institute and evaluated the incidence and risk factors of ILD. Results Of the 201 patients with HNSCC, ILD was observed in 9 patients (4.5%), 8 of whom had grade 3 or higher. High Krebs von den Lungen‐6 (KL‐6) and ≥50 pack‐years of smoking were significantly predictive of associated with ILD ( P = 0.00011 and 0.05, respectively). Conclusion The incidence of ILD in patients with HNSCC treated with cetuximab was <5%, but most of the ILD cases were severe. High KL‐6 and smoking histories might be predictive for ILD among patients with HNSCC.